What is William Blair’s Forecast for TARS FY2024 Earnings?

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) – Analysts at William Blair boosted their FY2024 EPS estimates for shares of Tarsus Pharmaceuticals in a research note issued to investors on Thursday, November 14th. William Blair analyst L. Hanbury-Brown now expects that the company will post earnings of ($3.26) per share for the year, up from their prior forecast of ($3.72). William Blair has a “Strong-Buy” rating on the stock. The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($3.41) per share. William Blair also issued estimates for Tarsus Pharmaceuticals’ Q4 2024 earnings at ($0.77) EPS, Q1 2025 earnings at ($0.72) EPS, Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at $0.22 EPS and FY2025 earnings at ($0.96) EPS.

A number of other brokerages have also commented on TARS. The Goldman Sachs Group upped their price objective on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a research report on Friday. Oppenheimer upped their price objective on shares of Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the company an “outperform” rating in a research report on Thursday, November 14th. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $54.20.

Tarsus Pharmaceuticals Stock Down 0.4 %

Shares of TARS opened at $44.63 on Monday. The company has a 50-day simple moving average of $38.11 and a 200-day simple moving average of $32.60. The firm has a market capitalization of $1.71 billion, a P/E ratio of -11.71 and a beta of 1.00. The company has a debt-to-equity ratio of 0.30, a quick ratio of 6.99 and a current ratio of 5.42. Tarsus Pharmaceuticals has a 52 week low of $15.60 and a 52 week high of $52.99.

Institutional Trading of Tarsus Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TARS. Swiss National Bank increased its stake in Tarsus Pharmaceuticals by 1.4% in the first quarter. Swiss National Bank now owns 42,433 shares of the company’s stock valued at $1,542,000 after acquiring an additional 600 shares during the period. Sei Investments Co. increased its stake in Tarsus Pharmaceuticals by 128.2% in the first quarter. Sei Investments Co. now owns 32,804 shares of the company’s stock valued at $1,192,000 after acquiring an additional 18,426 shares during the period. Russell Investments Group Ltd. increased its stake in Tarsus Pharmaceuticals by 38,907.8% in the first quarter. Russell Investments Group Ltd. now owns 30,036 shares of the company’s stock valued at $1,092,000 after acquiring an additional 29,959 shares during the period. ProShare Advisors LLC bought a new stake in Tarsus Pharmaceuticals in the first quarter valued at about $277,000. Finally, Vanguard Group Inc. increased its stake in Tarsus Pharmaceuticals by 14.5% in the first quarter. Vanguard Group Inc. now owns 1,826,632 shares of the company’s stock valued at $66,398,000 after acquiring an additional 231,131 shares during the period. Institutional investors own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.